Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
29.06
+0.86 (3.05%)
Apr 14, 2026, 4:00 PM EDT - Market closed

Genmab Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3,7203,1212,3902,0881,287
Revenue Growth (YoY)
19.19%30.59%14.48%62.20%-22.45%
Cost of Revenue
23814333--
Gross Profit
3,4822,9782,3572,0881,287
Selling, General & Admin
626549478385.16196.21
Research & Development
1,6061,4141,107800.55639.39
Other Operating Expenses
18543---
Total Operating Expenses
2,4172,0061,5851,186835.59
Operating Income
1,065972772902.03451.59
Interest Income
408645299459254.93
Interest Expense
-269-291-254-361.41-107.35
Total Non-Operating Income (Expense)
1393544597.59147.57
Pretax Income
1,2041,326817999.61599.17
Provision for Income Taxes
241193186214.89146.96
Net Income
9631,133631784.72452.2
Net Income to Common
9631,133631784.72452.2
Net Income Growth
-15.00%79.56%-19.59%73.53%-42.10%
Shares Outstanding (Basic)
622642653654654
Shares Outstanding (Diluted)
627647659660660
Shares Change (YoY)
-3.04%-1.88%-0.17%-0.06%0.24%
EPS (Basic)
1.551.770.971.200.69
EPS (Diluted)
1.541.750.961.190.68
EPS Growth
-12.32%82.98%-19.50%75.00%-42.86%
Shares Outstanding
642.38661.87660.75659.62657.19
Free Cash Flow
1,1491,0991,018517.44302.18
Free Cash Flow Growth
4.55%7.96%96.74%71.23%-69.95%
Free Cash Flow Per Share
1.831.701.540.780.46
Gross Margin
93.60%95.42%98.62%100.00%100.00%
Operating Margin
28.63%31.14%32.30%43.21%35.08%
Profit Margin
25.89%36.30%26.40%37.59%35.13%
FCF Margin
30.89%35.21%42.59%24.78%23.48%
EBITDA
1,1361,032815954.13489.52
EBITDA Margin
30.54%33.07%34.10%45.70%38.03%
EBIT
1,065972772902.03451.59
EBIT Margin
28.63%31.14%32.30%43.21%35.08%
Effective Tax Rate
20.02%14.56%22.77%21.50%24.53%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q